The DOI matches its Crossref record; 380 of the 380 references it cites were found in a registry or an index.
Tau-targeting therapies for Alzheimer disease: current status and future directions
Open accessAbstract
Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain, with associated loss of synapses and neurons, which eventually results in dementia. Many of the early attempts to develop treatments for AD focused on Aβ, but a lack of efficacy of these treatments in terms of slowing disease progression led to a change of strategy towards targeting of tau pathology. Given that tau shows a stronger correlation with symptom severity than does Aβ, targeting of tau is more likely to be efficacious once cognitive decline begins. Anti-tau therapies initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules. However, trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy. Currently, the majority of tau-targeting agents in clinical trials are immunotherapies. In this Review, we provide an update on the results from the initial immunotherapy trials and an overview of new therapeutic candidates that are in clinical development, as well as considering future directions for tau-targeting therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Research has indicated that tau pathology has a stronger correlation with cognitive deficits than Aβ plaques, indicating that treatment benefits from targeting tau may outweigh those from concentrating only on amyloid clearance [94,95].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Masliah, E., Rockenstein, E. M., Mante, M., Crews, L. A., Spencer, B. J., Adame, A., Patrick, C., Trejo, M., Ubhi, K. K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 422
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
Curcumin as “Curecumin”: From kitchen to clinic
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.016 · Cited by 2,274
Research works printed but not linked: 19
- Alzforum. Antisense therapy stifles CSF tau in mild Alzheimer’s disease. Alzforum https://www.alzforum.org/news/conference-coverage/antisense-therapy-stifles-csf-tau-mild-alzheimers-disease-0 (2021).
- Alzforum. First hit on aggregated tau: antisense oligonucleotide lowers tangles. Alzforum https://www.alzforum.org/news/conference-coverage/first-hit-aggregated-tau-antisense-oligonucleotide-lowers-tangles (2023).
- Ryan, J. M. et al. Phase 1 study in healthy volunteers of the O-GlcNAcase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies [abstract O1-12-05]. Alzheimers Dement. 14 (7S Part 4), 251 (2018).
- Shcherbinin, S. et al. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: translation from rat to human: neuroimaging/evaluating treatments. Alzheimers Dement. 16, e040558 (2020).
- Alzforum. Tau inhibitor fails again – subgroup analysis irks clinicians at CTAD. Alzforum https://www.alzforum.org/news/conference-coverage/tau-inhibitor-fails-again-subgroup-analysis-irks-clinicians-ctad (2016).
- Alzforum. In first phase 3 trial, the Tau drug LMTM did not work. Period. Alzforum http://www.alzforum.org/news/conference-coverage/first-phase-3-trial-tau-drug-lmtm-did-not-work-period#show-more (2016).
- Alzforum. First round of FTD therapeutics fell short, but many more are up and running. Alzforum https://www.alzforum.org/news/conference-coverage/first-round-ftd-therapeutics-fell-short-many-more-are-and-running (2016).
- Boutajangout, A., Ingadottir, J., Davies, P. & Sigurdsson, E. M. Passive tau immuntherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy [abstract P3-427]. Alzheimers Dement. 6 (4S Part 19), S578 (2010).
- Alzforum. Active tau vaccine: hints of slowing neurodegeneration. Alzforum https://www.alzforum.org/news/conference-coverage/active-tau-vaccine-hints-slowing-neurodegeneration (2020).
- UCB. UCB presents UCB0107 anti-Tau immunotherapy Phase I study Results at World Movement Disorders Conference®. UCB https://www.ucb.com/stories-media/Press-Releases/article/UCB-presents-UCB0107-anti-Tau-immunotherapy-Phase-I-study-results-at-World-Movement-Disorders-Conference (2019).
- Alzforum. N-terminal tau antibodies fade, mid-domain ones push to the fore. Alzforum https://www.alzforum.org/news/conference-coverage/n-terminal-tau-antibodies-fade-mid-domain-ones-push-fore (2021).
- Alzforum. More tau antibodies bid adieu; semorinemab keeps foot in door. Alzforum https://www.alzforum.org/news/conference-coverage/more-tau-antibodies-bid-adieu-semorinemab-keeps-foot-door (2021).
- Eisai. Eisai presents data showing quantification of tau microtubule binding region in cerebrospinal fluid and the identification of a target engagement biomarker for the new anti-tau antibody E2814 at Alzheimer’s Association International Conference (AAIC) 2019. Eisai https://www.eisai.com/news/2019/news201955.html (2019).
- Horie, K. et al. Quantification of the tau microtubule binding region (MTBR) in cerebrospinal fluid and subsequent validation of target engagement assay for E2814, a novel anti-tau therapeutic antibody. Alzheimers Dement. 15(7S Part 31), 1598–1599 (2019).
- Zhou, J. et al. E2814: an anti-tau therapy engages its CNS target and affects the downstream tangle-specific biomarker MTBR-tau243 in dominantly inherited Alzheimer’s disease [abstract]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online 2023 (2023).
- Rawal, S. et al. Safety, pharmacokinetics and immunogenicity of single and multiple ascending doses of the anti-tau therapeutic antibody E2814: a phase 1, first-in-human (FIH) study in healthy subjects [abstract P1-909]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).
- Galpern, W. R. et al. A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-tau antibody JNJ-63733657 in healthy subjects [abstract P1-052]. Alzheimers Dement. 15 (7S Part 5), 252–253 (2019).
- Prothena. Prothena reports topline phase 1 single ascending dose study results of PRX005, a novel anti-MTBR-tau antibody for the potential treatment of Alzheimer’s disease. Prothena https://ir.prothena.com/investors/press-releases/news-details/2023/Prothena-Reports-Topline-Phase-1-Single-Ascending-Dose-Study-Results-of-PRX005-a-Novel-Anti-MTBR-Tau-Antibody-for-the-Potential-Treatment-of-Alzheimers-Disease/default.aspx (2023).
- Martenyi, F. et al. PRX005, a novel anti-MTBR tau monoclonal antibody: results from a first-in-human double-blind, placebo-controlled, single ascending dose phase 1 study [abstract P1-727]. Presented at the Alzheimer’s Association International Conference, Amsterdam, Netherlands, and Online (2023).
Cited by
Sorted by citations
Items 201–300 of 372
Brain peptides in Alzheimer’s disease - pathophysiology and therapeutic advances
Pahal, S., Gupta, A., Kumar, V., Singh, P. B. R. P., Kaushik, M., Pahal, V., Atluri, G., & Chaudhary, A. (2026) · Cell and Tissue Research · doi:10.1007/s00441-026-04055-8 · Cited by 3
Mo, C., Bajgai, J., Rahman, M. H., Ma, H., Pham, T. T., Zhang, H., Cao, B., Jeong, E., Kim, C.-S., & Lee, K. J. (2026) · Antioxidants · doi:10.3390/antiox15030404 · Cited by 2
Viola, G., Sperotto, A., Palmioli, A., Tira, R., Munari, F., Assfalg, M., Airoldi, C., & D’Onofrio, M. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c17659 · Cited by 2
Paidi, R. K., Gorai, S., Mondal, S., & Pahan, K. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70432 · Cited by 2
The influence of beta-amyloid and tau proteins on cognitive changes in Parkinson's disease
Abraham, B., Carl, S., Ye, L., Wegner, F., Höllerhage, M., Westhoff, M. S., Konen, F. F., Schneidereit, I. V., Skripuletz, T., & Klietz, M. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108332 · Cited by 2
RNA-based therapeutics for Alzheimer’s disease and related tauopathies: challenges and opportunities
Rajbanshi, B., Brentari, I., Denti, M. A., Cummings, J. L., & Guruacharya, A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100585 · Cited by 2
Baskar, G., & Kandasamy, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.012 · Cited by 2
Lai, Y., Pan, J., Gu, Y., Zhou, C., Yang, W., Zhao, Q., Zhu, Z., Duan, Y., Lei, L., Fu, Y., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c05275 · Cited by 2
Alzheimer’s Disease: An Attempt of Total Recall
Bolshakov, A. P., Gerasimov, K., & Dobryakova, Y. V. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240620 · Cited by 2
Ning, Y., Zhang, Y., Jiang, T., Feng, J., Zhan, J., Ou, C., & Wang, L. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.12.005 · Cited by 2
Rahman, M., Sharma, P., Chattopadhyay, T., & Saroja, S. R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108396 · Cited by 2
Shang, S., Zhao, X., Zhang, Q., Zhao, G., Wang, H., & Lu, X. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00666 · Cited by 2
Qin, C., Li, D., Zhang, J., Yin, Z., & Li, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094372 · Cited by 2
Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease
Fu, C.-L., Li, X., Liu, X., Zheng, Y., Ma, X., Zhang, B., Chen, S. X., Hu, L., Su, S., Wang, X., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00498-1 · Cited by 2
Identification of TMED10 as A Regulator for Neuronal Exocytosis of Amyloid Beta 42
Meng, P., Sha, L., Yu, X., Wang, Y., Zhang, E., Meng, K., Li, B., Zhao, Q., & Xu, Q. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01492-3 · Cited by 2
Therapeutic Modalities Targeting Tau Protein in Alzheimer’s Disease
Schreiner, T. G., Iacob, L., Vasilache, C., & Schreiner, O. D. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2030032 · Cited by 2
Alsaadi, T. M., Almadani, A., Alrukn, S., Hassan, A., Sarathchandran, P., Shatila, A. O., Szólics, M., Benito, D., İnce, S., & Krieger, D. W. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00833-8 · Cited by 2
Mattioni, A., Carsetti, C., Bruqi, K., Caputo, V., Cianfanelli, V., Bacalini, M. G., Casa, M., Gabelli, C., Giardina, E., Cestra, G., et al. (2024) · medRxiv · doi:10.1101/2024.08.13.24311780 · Cited by 2
Morito, T., Qi, M., Kamano, N., Sasaguri, H., Bez, S., Foiani, M. S., Duff, K., Benner, S., Endo, T., Hama, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.15.623736 · Cited by 2
Novel Imaging Biomarkers for Brain PET Imaging
Landau, A. M. (2025) · Biomolecules · doi:10.3390/biom15040517 · Cited by 2
Preclinical Development of a Vectorized Artificial miRNA Gene Therapy for TauopathiesPreprint
Garza, I. T., Snyder, B., Holmes, S. K., Pearce, K. M., Knight, K. L., & Bailey, R. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.12.681935 · Cited by 2
Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk
Cohen, C. E., Fernandez, S., Yaman, U., Ehyaei, A. R., Kodosaki, E., Askarova, A., Porter, T., O’Brien, E., Study, A. I. B. A. L., Initiative, A. D. N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02036-1 · Cited by 1
Hou, X., Hou, L., Wang, Y., Wang, X.-Y., Jiang, Z.-Q., Sun, X., Ding, L., & Liu, W. (2024) · Analytical Chemistry Letters · doi:10.1080/22297928.2024.2411382 · Cited by 1
Lin, C., Huang, J.-H., Lin, P.-H., Chen, T.-B., Wang, L.-M., Huang, Y., & Chen, K.-L. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137134 · Cited by 2
Photobiomodulation Ameliorates Neuronal Damage in an Amyloid-Beta Induced Rat Model
Li, N., Liu, N., Ye, Y., Shi, H., Shi, J., Luo, G., Guo, J., Liu, Y., & Chen, H. (2025) · IEEE Journal of Selected Topics in Quantum Electronics · doi:10.1109/jstqe.2025.3564366 · Cited by 1
Liu, H., Liu, X., Tian, F., Chen, Y., Li, J., Wang, X., Qiu, W., Wang, X., Ma, C., & Ge, W. (2025) · Advanced Science · doi:10.1002/advs.202506044 · Cited by 1
Kemppainen, S., Aramburu-Núñez, M., Koivisto, H., Posado-Fernández, A., Felix-Garcia, M. R., Nurminen, K., Häkli, S., Abellí‐Deulofeu, E., Kaisto, M., Custodia, A., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115315 · Cited by 1
Katel, S., Cicalo, J., Vasciaveo, V., Vecchio, L. M., Carrión, J., Leann, M., Huerta, P. T., Choksi, J. D., Aubert, I., Marambaud, P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101563 · Cited by 2
Hedna, R., Relave, E. T., Robin, M., Kovacic, H., & Breuzard, G. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100309 · Cited by 1
Role of triterpenoid derivatives from Centella asiatica as quantum chemical calculations
Chockchowwat, W., Hannongbua, S., & Saparpakorn, P. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2578225 · Cited by 1
Lithium mitigates hippocampal tau pathology in a rodent model of traumatic brain injury
Donison, N. S., Palik, J., Hintermayer, M. A., Volkening, K., & Strong, M. J. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02170-1 · Cited by 1
Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1
Adeoye, B. O., Akano, O. P., Awojebe, D. R., Ogunbiyi, B. T., Adeoye, A. D., Ukangwa, N. A., Elizabeth, O. A., Olosunde, O. A., & Oyebanji, A. H. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10184-9 · Cited by 1
An overview of gene and cell therapy approaches for Alzheimer’s disease
Heidari, Z., Zakaee, A., Vafadar, A., Alavimanesh, S., Charami, H., Jamali, Z., Jahromi, A. H., Rakhsha, A., & Savardashtaki, A. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01763-y · Cited by 1
Yu, W., Zhuang, D., Wang, K., & Qu, Y. (2026) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2610481 · Cited by 1
N- Salicyloyl Tryptamine Derivatives Improve Mitochondrial Function To Treat Alzheimer’s Disease
Zeng, J., Zhao, Y., Chen, Y., Wu, K., Yang, C., Wu, Y., Pang, G., Zhang, M., Wen, H., Wang, Z., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c12400 · Cited by 1
Datta, D., Wang, M., & Arnsten, A. F. T. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1750092 · Cited by 1
Kynurenic acid derivatives in treatment for Alzheimer's disease
Pavílek, B., Hajduová, D., Bortňák, D., & Milata, V. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118601 · Cited by 1
CTAD 2025: Key trends redefining therapeutic and diagnostic strategies in Alzheimer's disease
Yuan, M., & Zhou, H.-Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261430764 · Cited by 1
Longitudinal Evaluation of 18 F-MK-6240 Along the Alzheimer Disease Continuum
Giarratana, A. O., Jonaitis, E. M., Przybelski, R. J., Cody, K. A., Betthauser, T. J., Cadman, R. V., Alberson, S. F., Christian, B. T., & Johnson, S. C. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271127 · Cited by 1
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
Cao, K., Xie, J., Liang, X., Li, Y., Gong, H., & Luo, H. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00917 · Cited by 2
Jiang, Y., Tetlow, A. M., Lin, Y., Ji, C., Ader, J., Laborc, K. F., Mar, A. C., Pan, R., Kong, X., Congdon, E. E., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea4205 · Cited by 2
Wang, Z., Jiang, X., Lin, J., An, R., He, Y., & Li, S. (2026) · Antioxidants · doi:10.3390/antiox15040515 · Cited by 1
Guedjdal, S., Leghay, C., Derisbourg, M. J., Eddarkaoui, S., Lecerf, S., Vermon, F., Caillierez, R., Bégard, S., Regost, C., Laloux, C., et al. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00550-8 · Cited by 2
Bagul, A. D., Irfan, M., Jaitak, A., Asati, V., Goyal, K., & Monga, V. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70248 · Cited by 2
Xin, J., Liu, J., Dong, H.-M., Yu, H., Xiao, Z., Hu, J.-N., Jiang, Q., Zhu, Y.-P., Feng, L., Feng, Y., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3243-2 · Cited by 2
Jin, S., Guo, B., Hao, W., Su, X., Zhang, T., & Liu, C. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00582 · Cited by 1
The tango of immune and neural cells: orchestrating neuroinflammation mediated brain disorders
Wu, Y., Lyu, W., Xie, X., Fu, X., Zhang, L., & Pan, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1827437 · Cited by 1
Masi, M., Oliviero, C., Govoni, S. M., Wolozin, B. L., Racchi, M., & Buoso, E. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179033 · Cited by 2
Advances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 1
Wong, J., Wang, T., Datta, R., Abdollahi, R. O., Li, J., Rowe, C. C., Henley, D. B., Kolb, H. C., Saad, Z. S., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71573 · Cited by 2
Design and delivery of targeting chimeras therapeutics in managing central nervous system disorders
Liu, S., Xu, W., Wang, M., Mao, Z., Zhou, J., Gu, X., Han, G., & Ding, Y. (2026) · Targetome · doi:10.48130/targetome-0026-0028 · Cited by 1
MINERVA: a public XAI-powered platform advancing multi-target discovery in Alzheimer’s disease
Gambacorta, N., Trisciuzzi, D., Mastrolorito, F., Leonetti, F., Altomare, C., de Candia, M., Catto, M., Amoroso, N., Ciriaco, F., & Nicolotti, O. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01253-y · Cited by 1
Early-stage research and new pharmacological targets in Alzhei-mer's dementia
Grecu, M., Romila, A., Moldovanu, S., Condratovici-Plesa, A., Anghel, L., Oprea, V. D., & Bocancia, L. A. (2026) · Balneo and PRM Research Journal · doi:10.12680/balneo.2026.1024 · Cited by 2
Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies
Yanagisawa, D., Ohgita, T., Kawashima, H., Yoshikawa, H., Saito, H., Tooyama, I., & Takata, K. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109084 · Cited by 1
CXCL10 contributes to female-specific pathological progression in tauopathy model mice
Uenishi, R., Kawata, R., Manabe, T., Matsuba, Y., Mihira, N., Takeo, T., Saido, T. C., Hijioka, M., & Saito, T. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03989-8 · Cited by 1
Sura, S., Jagadeesan, S., Moklas, M. A. M., Masrudin, S. S., Dandala, K. C. R., Judson, J. P., & Nor, N. H. M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12578-0 · Cited by 2
Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease
Dineshbhai, T. K., Rafaliya, D., Singh, A., Maheshwari, S., Lalan, M. S., & Chakraborthy, G. S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02341-z · Cited by 1
Essa, M., Ahmed, N., Kakar, A., Akber, W., Barech, S., Farooq, A., & Mumtaz, T. (2024) · doi:10.32948/ajsep.2024.03.28 · Cited by 1
Tomaszewski, M. R., Sukstanskii, A. L., Haley, H., Meng, X., Miller, C. O., & Yablonskiy, D. A. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120794 · Cited by 1
Amyloid-β is NOT only the most promising target for Alzheimer’s disease
Solomon, B., & Voronov‐Goldman, M. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00829 · Cited by 1
Endocannabinoids and Alzheimer's disease
Chen, C. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00026-8 · Cited by 1
Kusakabe, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-ctf7207 · Cited by 1
Dharavath, R. N., Bernardo, A. M., Marceau-Linhares, C., Marcotte, M. D., Mezo‐González, C. E., Wong, K. D., Pina‐Leblanc, C., Bouchet, A., Sharmin, D., Pandey, K. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.07.611810 · Cited by 1
Katel, S., Cicalo, J., Vasciaveo, V., Carrión, J., Leann, M., Huerta, P. T., Marambaud, P., Giliberto, L., & d’Abramo, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.13.638144 · Cited by 1
Tau Clearance Reverses Neuronal Dysfunction in Both Young and Aged C. elegansPreprint
Carroll, T., Johnson, G. V. W., & Nehrke, K. W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.23.661052 · Cited by 1
Jiang, Y., Tetlow, A. M., Lin, Y., Ji, C., Laborc, K. F., Mar, A. C., Pan, R., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662446 · Cited by 1
Targeting tau for Alzheimers disease through OGA inhibition
Rafii, M. S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100309 · Cited by 1
Xiao, Q., Gao, Z., Allen, S., Garza, D., Morimoto, R. I., & Kelly, J. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702105 · Cited by 1
Ji, Y., Mandal, P., Liu, J., Hu, W., Colon, B. D., Wan, C., Pan, R. W., Guo, D., Zhang, L., Gu, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.06.736894 · Cited by 1
Acceleration of GSK3α/β Exocytosis Inhibits TauopathyPreprint
He, D., Zhang, X., Su, J., Zhang, Q., Zhao, L., Wu, T.-Y., Ren, H., Jia, R., Lei, X., Hou, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4771345
Neurological Impact of Type I Interferon Dysregulation
Mylonas, A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1006023
Zhu, Y., Gelnaw, H., Leary, P., Raghuraman, R., Kamath, N., Kraja, A., Liu, J., Bai, Q., Higashijima, S., Burton, E. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618073
Capacci, A. G., & Paras, N. A. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch02
Selective Targeting of Pathogenic Tau Seeds via a Novel VHHPreprint
Gupta, A., Liu, R., Keely, D., Sunderman, V., Tak, Y., Konstantoulea, K., Terpack, S. J., White, C. L., Russ, W. P., Rizo, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632833
Could Blood Transfusion Increase the Risk of Alzheimer’s Disease? A Narrative Review
Li, X., Pei, R., Fei, Z., Chen, Z., Lin, F., Sun, P., & Cao, H. (2025) · Healthcare · doi:10.3390/healthcare13050452
A Federated Data Analysis Approach for the Evaluation of Surrogate Endpoints
Witte, D. D., Alonso, A., Stephenson, D. T., Karten, Y. J. G., Leuzy, A., Klein, G., & Molenberghs, G. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.70003
Melatonin ameliorates tauopathy and ferroptosis in P301S Tau transgenic mice
Jia, M., Wang, L., Guo, S.-Q., Liang, X.-T., Liu, X., Guo, S.-J., Wang, T., Zhong, M., Gao, H., & Guo, C. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.40
Hu, B., Shi, Y., Xiong, F., Chen, Y.-T., Zhu, X., Carrillo, E. C., Wen, X., Drolet, N. A., Rajpurohit, C. S., Xu, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.22.644756
Strategies for Treating Alzheimer’s: Current Approaches and Future Perspectives
Skuba, A., Załuska, K., Świdniak, A., Biskup, M., Bartoszek, A., Kopeć, K., Marut, A., Misiuk, J., Adamiuk, J., & Nykiel, S. (2025) · Quality in Sport · doi:10.12775/qs.2025.41.58829
Targeted therapy in older adults with Alzheimer disease: a review
Bulina, P. A., Popova, P. A., Dyatchina, L. S., Goliatina, M. M., Zaitseva, A., Abramenko, A. A., & Raevskii, K. P. (2025) · Russian Medicine · doi:10.17816/medjrf678002
Amyloid- and Tau-Targeted Therapies in Alzheimer’s Disease
Rajic, A. J., Galasko, D. R., & Tuszynski, M. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_17
Thottempudi, N., Franke, O., Samara, V. C., Musali, S. R., & Tabaac, B. J. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001978
Current Understanding and Therapeutic Advances in Alzheimer’s Disease
Chen, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au25268
de Oliveira, T. B., Galeriani, A. C. B., de Souza, J. R. R., Kawano, D. F., Trevisan, M. T. S., & Almeida, W. P. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf055
Tau deletion results in sex-dependent modulation of synaptic weakening in rat hippocampusPreprint
Ralph, L. T., Tidball, P., Salter, E. W., Park, B., Zhang, L., Wei, M., Joe, L. A., Thacker, J. S., Choi, S.-L., Kadia, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.07.665155
Discovery of a Novel Tau Pet Tracer: Design, Synthesis, Radio-Labeling, and Preclinical EvaluationsPreprint
Kuang, W., Yao, D., Zhang, N., Yao, Q., Xie, Y., Tian, R., & Wu, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5382845
Discovery of a Novel Tau Pet Tracer: Design, Synthesis, Radio-Labeling, and Preclinical EvaluationsPreprint
Kuang, W., Yao, D., Zhang, N., Yao, Q., Xie, Y., Tian, R., & Wu, X. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5382846
Aljabali, A. A. A., Alkaraki, A. K., & Obeid, M. A. (2025) · Current Neuropharmacology · doi:10.2174/011570159x371971250818110608
Quittot, N., Sivasankaran, D., Böken, D., Chen, Y., Chun, J. E., Wiedmer, A. E., Derosla, V., Martins, M., Brooks, F. A., Meisl, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.24.678227
Ballistic Microscopy (BaM)Preprint
Jijumon, A. S., Chang, R., & Prakash, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.07.681030
Antibodies targeting amyloid-β and Tau oligomers in Alzheimer’s disease
Chinnathambi, S., Rangappa, N., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.002
Das, J., Patel, B. M., Biswal, J., & Mishra, S. N. (2025) · Odisha Journal of Psychiatry · doi:10.4103/ojp.ojp_12_25
Alzheimer’s Disease Management Through the Gut-Brain Axis
Negi, P., Singh, N., & Sethi, P. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_17
Therapeutic Dendrimers: a Nanotechnology Approach to Alzheimer’s Disease
Mathure, D. M., Rahane, A., Ranpise, H. A., Karati, D., & Kumar, D. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00515-9
Yukti, Sharma, A., Dhar, S., Ojha, R., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.004
Conformation-based detection of tau seeds with a novel VHHPreprint
Gupta, A., Liu, R., Keely, D., Sunderman, V., Tak, Y., Konstantoulea, K., Terpack, S. J., White, C. L., Russ, W. P., Rizo, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-8274351/v1
N -Linked Glycosylation as a Driver of Tau Pathology and Neuronal TransmissionPreprint
Basta, T., Herlory, M., Holland, P., Stojkovic, R., Powell, W. C., & Walczak, M. A. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.690311
Neuronal PARIS-STAT3 axis drives tau pathology and glial activation in Alzheimer’s diseasePreprint
Song, J.-Y., Akkentli, F., Jo, H., Park, J., Ha, S., Ochoa, J., Troncoso, J. C., Kang, S.-U., Dawson, V. L., & Dawson, T. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.06.692741
Metadata
- Authors
- Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M.
- Affiliations
- New York University (US)
- NYU Langone Health (US)
- Corresponding author
- Sigurdsson, Einar M.
- Venue
- Nature Reviews Neurology
- Published
- 2023-10-24
- Volume
- 19
- Issue
- 12
- Pages
- 715-736
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC10965012
- OpenAlex
- W4387904363
- Cited by
- 371
- References
- 380
- Citations by year
- 2026: 125 · 2025: 170 · 2024: 74 · 2023: 1
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association (AG032611, AARF-22-924783)
- National Institutes of Health (NS120488)
- National Institute on Aging (R21AG069475, R01AG032611, T32AG052909)
- National Institute of Neurological Disorders and Stroke (RF1NS120488, R01NS120488, R01NS077239)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, tau protein, tau immunotherapy, tau aggregation, microtubule stabilization, post-translational modification, amyloid plaques, neurofibrillary tangles, clinical trials, drug candidates
- MeSH terms
- Aged, Alzheimer Disease, Humans, Immunotherapy, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
